« Back
Home /
VO-Ohpic (trihydrate)

VO-Ohpic (trihydrate)

Item no.	HY-13074-50mg
Manufacturer	MedChem Express
CASRN	476310-60-8
Amount	50 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 200 mg 50 mg 5 mg
Category	Metabolism Diabetes Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	98.0
Citations	[1]Mak LH, et al. Characterisation of the PTEN inhibitor VO-OHpic. J Chem Biol. 2010 Oct;3(4):157-63.\|[2]Rosivatz, E, et al. A small molecule inhibitor for phosphatase and tensin homologue deleted on chromosome 10 (PTEN). ACS Chem Biol. 2006 Dec 15;1(12):780-90.\|[3]Zu L, et al. PTEN inhibitors cause a negative inotropic and chronotropic effect in mice. Eur J Pharmacol. 2011 Jan 10;650(1):298-302. Biochem Pharmacol. 2020 Jan;171:113715.\|Biochem Pharmacol. 2019 Oct;168:82-90. \|Biochim Biophys Acta Mol Basis Dis. 2022 Jan 1;1868(1):166292.\|Biochim Biophys Acta Mol Basis Dis. 25 October 2021, 166292.\|BMC Cancer. 2019 Apr 25;19(1):391.\|Bone Res. 2018 Nov 10;6:32.\|Cancer Med. 2019 Aug;8(9):4265-4277.\|Cell Biol Toxicol. 2025 Feb 27;41(1):53.\|Cell Death Dis. 2019 May; 10(5): 329.\|Cell Stem Cell. 2022 Apr 7;29(4):545-558.e13.\|Clin Transl Med. 2020 Dec;10(8):e240.\|Clin Transl Med. 2022 Sep;12(9):e1061.\|Environ Sci Technol. 2020 Sep 1;54(17):10783-10796.\|Eur Rev Med Pharmacol Sci. 2019 May;23(10):4406-4413.\|Funct Integr Genomics. 2024 Apr 3;24(2):71.\|Int Immunopharmacol. 2021 Dec 23;103:107840.\|Int J Mol Med. 2021 Apr 19.\|Int J Mol Sci. 2023 Jun 9, 24(12), 9954.\|iScience. 2024 June 19.\|J Adv Res. 2024 Sep 29:S2090-1232(24)00429-6.\|J Cell Mol Med. 2019 Nov;23(11):7535-7544.\|Mol Med Rep. 2018 Dec;18(6):5489-5501.\|Mol Med Rep. 2022 Jul;26(1):246.\|Mol Nutr Food Res. 2019 Dec;63(24):e1900418.\|Mol Vis. 2018 Jul 23;24:485-494.\|Redox Biol. 2019 Jan;20:390-401. \|Redox Biol. 2024 May 17:73:103200.\|Stem Cell Res Ther. 2019 Jul 29;10(1):217.\|Theranostics. 2019 Jul 9;9(16):4764-4778.\|Theranostics. 2019 Jul 9;9(18):5200-5213.\|Transl Psychiatry. 2021 Mar 26;11(1):185.\|Phytomedicine. 2023 Sep 22, 155117.\|SSRN. 2023 Jul 17.
Smiles	O=C1[O-][V+2]2([O-]C(C3=[N]2C=CC=C3O)=O)([O-]C4=CC=CN=C14)([OH2])=O.[H+].[3H2O]
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	476310-60-8
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Autophagy; PTEN
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	415.20
Product Description	VO-Ohpic trihydrate is a highly potent inhibitor of PTEN with an IC50 of 46±10 nM.
Manufacturer - Research Area	Cancer
Solubility	DMSO: ≥ 50 mg/mL\|H2O: < 0.1 mg/mL
Manufacturer - Pathway	Autophagy; PI3K/Akt/mTOR
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-13074-50mg-safety-datasheet.pdf